Post hoc analysis of the FUTURE 2 study revealed that Psoriatic Arthritis Disease Activity Score (PASDAS)-based remission or low disease activity (LDA) was sustained at 2 years in patients with psoriatic arthritis (PsA) treated with secukinumab who had achieved remission or LDA at 16 weeks. Remission or LDA occurred at the highest rate in TNF inhibitor-naive patients with PsA, and patients who achieved remission or LDA had a greater improvement in patient-reported outcomes (such as physical function and health-related quality of life) at 2 years than those in whom disease activity remained high.